[Antimetabolites in the treatment of acute human leukoses. Mechanism of action and conditioning factors in the cellular response to drugs. II].
D000963:Antimetabolites / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D001374:Azacitidine / Q000494:pharmacology; D001375:Azaguanine / Q000494:pharmacology; D001380:Azauridine / Q000494:pharmacology; D002463:Cell Membrane Permeability / Q000187:drug effects; D003561:Cytarabine / Q000494:pharmacology; D004273:DNA, Neoplasm / Q000096:biosynthesis; D005472:Fluorouracil / Q000494:pharmacology; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects*; D007945:Leukemia, Lymphoid / Q000188:drug therapy* / Q000378:metabolism; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000378:metabolism; D015122:Mercaptopurine / Q000494:pharmacology; D008727:Methotrexate / Q000494:pharmacology; D011687:Purines / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology
D000963:Antimetabolites; D004273:DNA, Neoplasm; D011687:Purines; D011743:Pyrimidines; D003561:Cytarabine; D001380:Azauridine; D015122:Mercaptopurine; D001374:Azacitidine; D001375:Azaguanine; D005472:Fluorouracil; D008727:Methotrexate
Gli antimetaboliti nella terapia delle leucosi acute umane. Meccanismo d'azione e fattori condizionanti la risposta cellulare ai farmaci. II